Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Hyperlipidaemia is a characteristic feature not only of the nephrotic syndrome but also of chronic renal disease without the features of that syndrome. There is evidence for disordered lipid metabolism in patients with chronic renal disease. In these patients the disordered lipid metabolism, the precise cause of which is unknown, is characterised by hypertriglyceridaemia, the aetiology of which is probably multifactorial. Hyperlipidaemia is an important potential risk factor in the aetiology of cardiovascular disease, which may be a leading cause of death in patients undergoing long-term maintenance haemodialysis therapy.
 ...
PMID:Disorders of blood-lipids in renal disease. 4 91

1. To determine lipoprotein (LP) abnormalities, clinical characteristics and preclinical signs of atherosclerosis in asymptomatic subjects with hyperlipidaemia serum cholesterol and triglyceride (TG) concentrations were determined in 20,000 subjects attending a health control centre linked to their employment. 2. Three hundred and fourteen asymptomatic subjects with serum cholesterol larger than or equal to 350 mg/100 ml and/or TG larger than or equal to 3.50 mmol/l in the screening test but without signs or symptoms of secondary hyperlipideaemia or history of cardiovascular disease were examined further. 3. LP analysis with preparative ultracentrifugation separating very lof cholestrol and TG concentrations in each fraction was performed. LP paper electrophoresis was run on while serum and on top and bottom fractions after separation in the ultracentrifuge at d=1.006. Typing of hyperlipoproteinaemia (HLP) was performed according to WO based upon the values of for VLDL and LDL. Exercise ECG was performed on a heart rate controlled bicycle ergometer. The subjects worked at constant predetermined heart rates. ECG at rest and furing exercise was interpreted without knowledge of whether or not the subject has HLP and coded according to the Minnesota criteria. Digital pulse plethysmography was performed on the lower limbs....
 ...
PMID:Studies in asymptomatic primary hyperlipidaemia. Clinical, biochemical and physiological investigations. 17 Aug

Among the identified precursors of cardiovascular disease hypertension acts as a major risk factor. Hyperlipidaemia, hyperglycaemia and cigarette smoking are the other major factors that increase the risk of symptomatic cardiovascular disease (CVD). Other factors influence (obesity, stress, hyperuricaemia, etc.) but are not independent risk factors. More definitive information on the efficacy of multifactorial intervention is needed.
 ...
PMID:Risk factors in hypertension and ischaemic heart disease. 50 35

The differences in cardiovascular health status between participants and non-participants were examined in a population-based cardiovascular study. Telephone interviews with non-respondents revealed generally more cardiovascular disease but less hyperlipidemia and family history of cardiovascular disease. Non-respondents did not differ regarding known hypertension, diet or drug therapy for hyperlipidemia, or egg use. Non-respondents were more likely to be cigarette smokers. Because the amount of non-respondent bias in the study was small while the response rate was high, respondents were generally representative of the target population. However, the observed differences could have produced spuriously high estimates of risk factor prevalence, low estimates of disease prevalence, and biased relative risks if the non-response rate and/or the baseline differences had been considerably larger.
 ...
PMID:Differences between respondents and non-respondents in a population-based cardiovascular disease study. 72 5

1. There were significant correlation between hyperlipidemia and obesity, hypertension, abnormal ECG and abnormal eyeground. 2. The incidence of cerebral hemorrhage was closely associated with hypertension but not with hyperlipidemia. 3. It was proved that hypertension with both hyper-Ch and hyper-TG was highly related to the development of cerebral infarction. 4. It seemed that the incidence of myocardial infarction and angina pectoris was related to hypertension with hyper-Ch. 5. Therefore, the present study suggested that the control of hypercholesterolemia and hypertriglyceridemia was useful for the prevention of cerebro-cardiovascular disease.
 ...
PMID:The epidemiological study on the correlation between serum lipids and cerebro-cardiovascular disease. 111 82

The role of triglycerides in cardiovascular disease is a controversial subject. Despite differences of opinion, present data allow a certain number of conclusions to be drawn. Hyperchylomicronemia is not associated with atherosclerosis, whereas type III hyperlipidemia is very atherogenic. These two abnormalities are, however, rare, and the majority of hypertriglyceridemias are, in practice, associated with increased very low density lipoproteins. Many epidemiological trials do not identify hypertriglyceridemia as an independent risk factor when the cholesterol and, in particular, the HDL cholesterol levels, are taken into consideration. Nevertheless, these results must be interpreted with caution as hypertriglyceridemia represents a very heterogeneous entity which is closely related to many factors which affect coronary risk (hypertension, insulin resistance, sedentarity, and even tobacco consumption). Therefore, hypertriglyceridemia and hypo-HDL-emia may be the result of the same primary abnormality; as the HDL-cholesterol level is more stable, it is the parameter which will be identified as a protective factor in epidemiological trials. The available data is insufficient to affirm that therapeutic lowering of triglycerides is accompanied by a reduced coronary risk because none of the large scale trials were designed to analyse this problem. Despite these epidemiological data, the measurement of serum triglyceride levels remains important in patients with hyperlipidemia.
 ...
PMID:[Role of triglycerides in cardiovascular diseases]. 129 43

The management of hyperlipidemia in individuals aged 60 or over is a serious problem, given the frequency of metabolic abnormalities in this age group. The decision to treat must take into account a number of uncertainties. Hypercholesterolemia is a risk factor in the elderly and, in general, its importance varies like the other major risk factors (hypertension and smoking): the relative risk decreases with age but this decrease in relative risk is associated with an increase in the absolute risk because the prevalence of cardiovascular disease greatly increases with age. The serum cholesterol level increases with age but the physiopathological mechanism os this increase is poorly understood (reduction in the number of LDC receptors?). In the over 70s, serum cholesterol levels decrease, probably because of a selection due to the deaths of subjects at higher risk. No therapeutic trials have been performed to evaluate the effects of lowering the serum cholesterol in the over 60s. In addition, strict application of international recommendations in this age group would result in a large number of therapeutic interventions, the value of which would be questionable. Under these conditions, practical clinical advice is based on reasoned extrapolation of epidemiological data obtained in middle-aged men. Treatment should therefore be reserved for sever forms of hyperlipidemia, taking into consideration the life expectancy of the individual.
 ...
PMID:[Hyperlipidemia in patients over 60 years old]. 129 49

An increased incidence of hyperlipidemia places kidney graft recipients at increased risk for cardiovascular disease and may contribute to a decline in graft function. A study was undertaken to evaluate the safety and efficacy of lovastatin in these patients. Twelve kidney graft recipients with stable graft function and a cholesterol (chol) level over 250 mg/dl (6.46 mmol/l) were included. The lipid-lowering treatment consisted of 20 mg lovastatin daily, and all patients received immunosuppression with ciclosporin (CS) and prednisolone. Total chol decreased by 27% (300 +/- 56 to 219 +/- 28 mg/dl; 7.76 +/- 1.45 to 5.66 +/- 0.72 mmol/l; p < 0.01), LDL-chol by 35% (220 +/- 38 to 143 +/- 17 mg/dl; 5.69 +/- 0.98 to 3.70 +/- 0.44 mmol/l; p < 0.01) and triglycerides by 33% (207 +/- 127 to 138 +/- 56 mg/dl; 2.36 +/- 1.44 to 1.57 +/- 0.64 mmol/l; p < 0.05). HDL-chol increased by 10% (57 +/- 11 to 63 +/- 13 mg/dl; 1.47 +/- 0.28 to 1.63 +/- 0.34 mmol/l; NS). The ratio of total chol/HDL-chol, a generally accepted risk predictor of atherosclerosis, fell from 5.4 +/- 1.3 to 3.3 +/- 1.2, p < 0.01. Lipoprotein (a) [lp(a)], an independent risk predictor for atherosclerosis, was also evaluated at baseline and after 6 months of lovastatin treatment and showed a decrease of 39% (32.9 +/- 27.6 to 19.9 +/- 22.9 mg/dl; 0.85 +/- 0.71 to 0.51 +/- 0.59 mmol/l; p < 0.05). No adverse side effects were seen at this dosage, and hepatic and renal parameters remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Treatment of hyperlipidemic kidney graft recipients with lovastatin: effect on LDL-cholesterol and lipoprotein (a). 130 Apr 34

The medical effects of modest weight reduction (approximately 10% or less) in patients with obesity-associated medical complications were reviewed. The National Library of Medicine MEDLINE database and the Derwent RINGDOC database were searched to identify English language studies that examined the effects of weight loss in obese patients with serious medical complications commonly associated with obesity (non-insulin dependent diabetes mellitus (NIDDM or type II), hypertension, hyperlipidemia, hypercholesterolemia, and cardiovascular disease). Studies in which patients experienced approximately 10% or less weight reduction were selected for review. Studies indicated that, for obese patients with NIDDM, hypertension or hyperlipidemia, modest weight reduction appeared to improve glycemic control, reduce blood pressure, and reduce cholesterol levels, respectively. Modest weight reduction also appeared to increase longevity in obese individuals. In conclusion, a large proportion of obese individuals with NIDDM, hypertension, and hyperlipidemia experienced positive health benefits with modest weight loss. For patients who are unable to attain and maintain substantial weight reduction, modest weight loss should be recommended; even a small amount of weight loss appears to benefit a substantial subset of obese patients.
 ...
PMID:Beneficial health effects of modest weight loss. 132 66

Cardiovascular disease is a major cause of death. There is evidence that this disease is predicted and its progression influenced by various factors (e.g. hyperlipidaemia). In this review, we consider aspects of platelet structure and function which may explain how this cell type contributes to the pathogenesis of vascular disease. The platelet also contains bioamines (serotonin, 5-HT; histamine) which are potent vasoactive substances. Studies involving patients with peripheral vascular disease (PVD) where abnormalities in platelet function (platelet aggregation and platelet shape change) and in bioamine status (vascular, platelet and plasma bioamine concentrations) are reviewed. We also discuss how platelet activation (in vitro) and plasma lipids influence intraplatelet bioamine status. Finally, we report in vitro evidence of the effect of two drugs prescribed to PVD patients: aspirin and naftidrofuryl. Aspirin is an ineffective inhibitor of 5-HT-induced whole blood platelet aggregation whereas naftidrofuryl is effective in the presence or absence of aspirin. By identifying and altering the factors which contribute to the pathogenesis of atherosclerosis we will be better equipped to prevent, reverse or retard this process.
 ...
PMID:Serotonin, histamine and platelets in vascular disease with special reference to peripheral vascular disease. 134 86


1 2 3 4 5 6 7 8 9 10 Next >>